New expense-management rules on bancassurance commissions took effect in July, and they are landing in a market where premium growth was already decelerating. Fitch Ratings expects growth to remain modest through the rest of 2026 as insurers absorb the near-term sales impact of tighter commission economics and adjust their distribution models accordingly.
Premiums across China's life insurance industry rose 6.2% year-on-year in the first quarter of 2026 to 2.31 trillion yuan, with life insurers' income up 7.3%, according to data from the Insurance Association of China. That pace has since eased: Fitch puts premium growth at 3.6% year-on-year for the first half of 2026, with the bancassurance commission rules - effective July - expected to keep growth subdued through the remainder of the year.
The bancassurance channel, where insurers sell policies through bank branches, has become the industry's dominant sales route in recent years. The commission squeeze traces to a specific regulatory mechanism: the National Financial Regulatory Administration's "integration of reporting and conduct" requirement, which forces insurers to align actual expenses with filed actuarial assumptions. Enforcement of the rule has already cut commission rates and reshaped profit models across both the bancassurance and agency channels, according to Chambers and Partners' 2026 China insurance practice guide. Fitch expects the tightening to weigh on sales in the near term while pushing insurers toward healthier, less commission-dependent growth over time.
The pressure is not isolated to China. Fitch's broader 2026 outlook for Asia-Pacific insurance maintained a neutral rating for the region overall but designated life insurance in both China and Taiwan as "deteriorating," pointing to structural pressures distinct from the rest of the regional market.
Slower top-line growth does not necessarily mean weaker profitability - and in the Chinese market's case, the same regulatory changes squeezing sales are simultaneously improving margin quality.
Swiss Re Institute's China sigma report found that new business value margins at listed life insurers expanded by roughly one to four percentage points in the period under review, driven by the same commission controls now depressing sales, alongside a shift toward longer-term, floating-rate products and productivity gains among agents.
Fitch's analysis points in the same direction. Insurers are shifting toward participating products with lower guaranteed rates - policies that share investment performance with policyholders rather than locking in fixed returns. These generate lower new business value margins than traditional savings products but reduce insurers' sensitivity to interest-rate changes over the long term, supporting a more sustainable model in the current low-rate environment. For intermediaries advising clients on Chinese life insurance products, the shift matters practically: clients used to expecting guaranteed-return structures will increasingly encounter products where the investment outcome is shared rather than fixed, and the advice conversation changes accordingly.
The other side of the ledger is capital. Fitch expects solvency ratios to come under pressure from higher reserve requirements, falling interest rates, and rising equity exposure as insurers seek returns in a low-yield environment that has eroded their traditional advantage over bank wealth-management products.
That is showing up in the bond market. Smaller and mid-sized insurers continued issuing subordinated and perpetual bonds at an elevated rate in the first half of 2026, following the expiry of transitional capital rules under China's risk-based solvency framework - known as C-ROSS Phase II - at the end of 2025. For intermediaries advising clients on carrier selection within the Chinese market, the solvency trajectory at smaller and mid-sized insurers is a counterparty consideration worth tracking. The same insurers most dependent on commission-driven bancassurance volumes are also those most likely to face capital pressure as the regulatory environment tightens.
Beyond the near-term squeeze, the structural direction is more supportive. GlobalData forecasts the Chinese life insurance market will grow from approximately 4.9 trillion yuan in 2026 to 6.6 trillion yuan by 2030, a compound annual growth rate of 7.9%, supported by China's gradual increase to the statutory retirement age and continued product innovation. That projection carries the uncertainty inherent in any five-year forecast, but the demographic and regulatory tailwinds behind it are real.
For now, intermediaries and insurers operating in the Chinese life market are navigating a narrower path: slower premium growth, tighter commission economics, a product mix shifting away from guaranteed returns, and capital markets watching solvency buffers closely at the smaller end of the industry. The rebalancing may produce a healthier market in 2027 and beyond. The near-term path there is more constrained than the 7.3% first-quarter growth figure suggests.
